Pharmafile Logo
Pharmafocus logo
Advanced Search

hereditary angioedema

Showing 3 posts of 3 posts found.

hsm_mobile_clinical_trial_istock-872676342

CSL Behring’s angioedema treatments receives NICE recommendation

September 26, 2025
Regulatory Affairs, Research and Development Andembry, CSL Behring, hereditary angioedema

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …

News

CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany

June 26, 2025
Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access

CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …

News
Shire

Shire to acquire Dyax in $5.9 billion deal

November 2, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease

Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026